Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Genetically Engineered Cells (CART22 T Cells) for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Pediatric Patients

Trial Status: active

This phase I trial studies the side effects of CART22 T cells in treating pediatric patients with B-cell acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). This study will take the patient's white blood cells (T cells) and change them to turn against the cancer. These changed cells are called CART22 T cells. The T cells will be changed in a way that will allow the cells to identify and kill the tumor cells. This change tells the T cells to go to the tumor cells and turn "on" and potentially kill the tumor cells. The modification is done by gene transfer and results in a genetic change to the T cells. This allows the changed T cells to recognize tumor cells and normal antibody-producing cells called B cells, but not other normal cells in the body.